CDIO
vs
S&P 500
CDIO
S&P 500
Over the past 12 months, CDIO has underperformed S&P 500, delivering a return of -89% compared to the S&P 500's +16% growth.
Stocks Performance
CDIO vs S&P 500
Performance Gap
CDIO vs S&P 500
Performance By Year
CDIO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cardio Diagnostics Holdings Inc
Glance View
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
